Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Refractive Errors, Eye Diseases
Trial Timeline
May 5, 2022 → Sep 10, 2022
NCT ID
NCT05294328About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution is a phase 2 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05294328. Target conditions include Presbyopia, Refractive Errors, Eye Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05431543 | Phase 2 | Completed |
| NCT05294328 | Phase 2 | Completed |
Competing Products
14 competing products in Presbyopia
Other Products from LENZ Therapeutics
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehiclePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + BrimonidinePhase 3
69
PRX-100 + PlaceboPhase 2
44